The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
The ability to elicit broadly neutralizing antibody responses against HIV-1 is a crucial goal for a prophylactic HIV-1 vaccine. Here, we discuss the difficulties of achieving broad HIV-1 neutralization in the context of both the effective annual human influenza virus vaccine and the need to develop a pandemic influenza vaccine. Immunogen-design strategies are underway to target functionally conserved regions of the HIV-1 envelope glycoproteins, and similar strategies might be applicable to pandemic influenza virus vaccine development. Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens.
Karlsson Hedestam
Gunilla B
GB
Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Fouchier
Ron A M
RA
Phogat
Sanjay
S
Burton
Dennis R
DR
Sodroski
Joseph
J
Wyatt
Richard T
RT
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D015195:Drug Design; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D009980:Influenza A virus / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D009500:Neutralization Tests; D014759:Viral Envelope Proteins / Q000276:immunology; D054299:env Gene Products, Human Immunodeficiency Virus / Q000276:immunology
D016915:AIDS Vaccines; D000914:Antibodies, Viral; D015483:HIV Antibodies; D007252:Influenza Vaccines; D014759:Viral Envelope Proteins; D054299:env Gene Products, Human Immunodeficiency Virus